Crispr Therapeutics Ag (CRSP)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2024 | 12-2023 | 12-2022 | 12-2021 | 12-2020 | |
| Sales | 37,314 | 371,206 | 1,198 | 914,963 | 719 |
| Gross Profit | 37,314 | 371,206 | 1,198 | 914,963 | 719 |
| Operating Expenses | 503,880 | 593,744 | 674,359 | 541,435 | 355,154 |
| Operating Income | -466,566 | -222,538 | -673,161 | 373,528 | -354,435 |
| Other Income | 103,901 | 71,816 | 22,661 | 6,003 | 6,379 |
| Pre-tax Income | -362,665 | -150,722 | -650,500 | 379,531 | -348,056 |
| Income Tax | 3,587 | 2,888 | -325 | 1,870 | 809 |
| Net Income Continuous | -366,252 | -153,610 | -650,175 | 377,661 | -348,865 |
| Net Income | $-366,252 | $-153,610 | $-650,175 | $377,661 | $-348,865 |
| EPS Basic Total Ops | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 |
| EPS Basic Continuous Ops | -4.34 | -1.94 | -8.36 | 4.97 | -5.29 |
| EPS Diluted Total Ops | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 |
| EPS Diluted Continuous Ops | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 |
| EPS Diluted Before Non-Recurring Items | -4.34 | -1.94 | -8.36 | 4.70 | -5.29 |
| EBITDA(a) | $-447,307 | $-202,701 | $-648,989 | $391,481 | $-343,394 |